Antiplatelet drug acting via purinergic receptors, not largely impacted by CYP2C19 polymorphism is:

Ref. KDT. Page. 629 Prasugrel is a prodrug , similar to Clopidogrel Thienopyridine drug class Irreversible antagonist of P2Y12 ADP receptors Rapidly absorbed, completely activated & exerts more consistent platelet inhibition. No interaction with CYP2C19 polymorphism Strong anti-platelet activity Bleeding complications are more serious and frequent. Contraindicated in patients with history of ischemic strokes and TIA’s